P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.
Identifieur interne : 003C17 ( Ncbi/Curation ); précédent : 003C16; suivant : 003C18P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.
Auteurs : Giorgio V. Scagliotti ; Rabab Gaafar ; Anna Nowak ; Nicholas J. Vogelzang ; Ute Von Wangenheim ; Nassim Morsli ; Derek Velema ; Sanjay PopatSource :
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [ 1556-1380 ] ; 2016.
DOI: 10.1016/j.jtho.2016.08.075
PubMed: 27676538
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001808
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001785
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001785
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :003C17
Links to Exploration step
pubmed:27676538Curation
No country items
Giorgio V. Scagliotti<affiliation><nlm:affiliation>Department of Oncology, University of Turin, Torino/ITALY.</nlm:affiliation>
<wicri:noCountry code="subField">Torino/ITALY</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>National Cancer Institute, Cairo University, Cairo/EGYPT.</nlm:affiliation>
<wicri:noCountry code="subField">Cairo/EGYPT</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>School of Medicine And Pharmacology Qeii, Medical Centre Unit, University of Western Australia, Crawley/WA/AUSTRALIA.</nlm:affiliation>
<wicri:noCountry code="subField">Crawley/WA/AUSTRALIA</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>US Oncology Comprehensive Cancer Centers of Nevada, Las Vegas/NV/UNITED STATES OF AMERICA.</nlm:affiliation>
<wicri:noCountry code="subField">Las Vegas/NV/UNITED STATES OF AMERICA</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/GERMANY.</nlm:affiliation>
<wicri:noCountry code="subField">Biberach/GERMANY</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Boehringer Ingelheim France S.A.S., Paris/FRANCE.</nlm:affiliation>
<wicri:noCountry code="subField">Paris/FRANCE</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Boehringer Ingelheim (Canada) Ltd./Ltée, Burlington/ON/CANADA.</nlm:affiliation>
<wicri:noCountry code="subField">Burlington/ON/CANADA</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Royal Marsden Hospital NHS Foundation Trust, London and Surrey/UNITED KINGDOM.</nlm:affiliation>
<wicri:noCountry code="subField">London and Surrey/UNITED KINGDOM</wicri:noCountry>
</affiliation>
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.</title>
<author><name sortKey="Scagliotti, Giorgio V" sort="Scagliotti, Giorgio V" uniqKey="Scagliotti G" first="Giorgio V" last="Scagliotti">Giorgio V. Scagliotti</name>
<affiliation><nlm:affiliation>Department of Oncology, University of Turin, Torino/ITALY.</nlm:affiliation>
<wicri:noCountry code="subField">Torino/ITALY</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gaafar, Rabab" sort="Gaafar, Rabab" uniqKey="Gaafar R" first="Rabab" last="Gaafar">Rabab Gaafar</name>
<affiliation><nlm:affiliation>National Cancer Institute, Cairo University, Cairo/EGYPT.</nlm:affiliation>
<wicri:noCountry code="subField">Cairo/EGYPT</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Nowak, Anna" sort="Nowak, Anna" uniqKey="Nowak A" first="Anna" last="Nowak">Anna Nowak</name>
<affiliation><nlm:affiliation>School of Medicine And Pharmacology Qeii, Medical Centre Unit, University of Western Australia, Crawley/WA/AUSTRALIA.</nlm:affiliation>
<wicri:noCountry code="subField">Crawley/WA/AUSTRALIA</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Vogelzang, Nicholas J" sort="Vogelzang, Nicholas J" uniqKey="Vogelzang N" first="Nicholas J" last="Vogelzang">Nicholas J. Vogelzang</name>
<affiliation><nlm:affiliation>US Oncology Comprehensive Cancer Centers of Nevada, Las Vegas/NV/UNITED STATES OF AMERICA.</nlm:affiliation>
<wicri:noCountry code="subField">Las Vegas/NV/UNITED STATES OF AMERICA</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Von Wangenheim, Ute" sort="Von Wangenheim, Ute" uniqKey="Von Wangenheim U" first="Ute" last="Von Wangenheim">Ute Von Wangenheim</name>
<affiliation><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/GERMANY.</nlm:affiliation>
<wicri:noCountry code="subField">Biberach/GERMANY</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Morsli, Nassim" sort="Morsli, Nassim" uniqKey="Morsli N" first="Nassim" last="Morsli">Nassim Morsli</name>
<affiliation><nlm:affiliation>Boehringer Ingelheim France S.A.S., Paris/FRANCE.</nlm:affiliation>
<wicri:noCountry code="subField">Paris/FRANCE</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Velema, Derek" sort="Velema, Derek" uniqKey="Velema D" first="Derek" last="Velema">Derek Velema</name>
<affiliation><nlm:affiliation>Boehringer Ingelheim (Canada) Ltd./Ltée, Burlington/ON/CANADA.</nlm:affiliation>
<wicri:noCountry code="subField">Burlington/ON/CANADA</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Popat, Sanjay" sort="Popat, Sanjay" uniqKey="Popat S" first="Sanjay" last="Popat">Sanjay Popat</name>
<affiliation><nlm:affiliation>Royal Marsden Hospital NHS Foundation Trust, London and Surrey/UNITED KINGDOM.</nlm:affiliation>
<wicri:noCountry code="subField">London and Surrey/UNITED KINGDOM</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27676538</idno>
<idno type="pmid">27676538</idno>
<idno type="doi">10.1016/j.jtho.2016.08.075</idno>
<idno type="wicri:Area/PubMed/Corpus">001808</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001808</idno>
<idno type="wicri:Area/PubMed/Curation">001785</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001785</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001785</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001785</idno>
<idno type="wicri:Area/Ncbi/Merge">003C17</idno>
<idno type="wicri:Area/Ncbi/Curation">003C17</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.</title>
<author><name sortKey="Scagliotti, Giorgio V" sort="Scagliotti, Giorgio V" uniqKey="Scagliotti G" first="Giorgio V" last="Scagliotti">Giorgio V. Scagliotti</name>
<affiliation><nlm:affiliation>Department of Oncology, University of Turin, Torino/ITALY.</nlm:affiliation>
<wicri:noCountry code="subField">Torino/ITALY</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gaafar, Rabab" sort="Gaafar, Rabab" uniqKey="Gaafar R" first="Rabab" last="Gaafar">Rabab Gaafar</name>
<affiliation><nlm:affiliation>National Cancer Institute, Cairo University, Cairo/EGYPT.</nlm:affiliation>
<wicri:noCountry code="subField">Cairo/EGYPT</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Nowak, Anna" sort="Nowak, Anna" uniqKey="Nowak A" first="Anna" last="Nowak">Anna Nowak</name>
<affiliation><nlm:affiliation>School of Medicine And Pharmacology Qeii, Medical Centre Unit, University of Western Australia, Crawley/WA/AUSTRALIA.</nlm:affiliation>
<wicri:noCountry code="subField">Crawley/WA/AUSTRALIA</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Vogelzang, Nicholas J" sort="Vogelzang, Nicholas J" uniqKey="Vogelzang N" first="Nicholas J" last="Vogelzang">Nicholas J. Vogelzang</name>
<affiliation><nlm:affiliation>US Oncology Comprehensive Cancer Centers of Nevada, Las Vegas/NV/UNITED STATES OF AMERICA.</nlm:affiliation>
<wicri:noCountry code="subField">Las Vegas/NV/UNITED STATES OF AMERICA</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Von Wangenheim, Ute" sort="Von Wangenheim, Ute" uniqKey="Von Wangenheim U" first="Ute" last="Von Wangenheim">Ute Von Wangenheim</name>
<affiliation><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/GERMANY.</nlm:affiliation>
<wicri:noCountry code="subField">Biberach/GERMANY</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Morsli, Nassim" sort="Morsli, Nassim" uniqKey="Morsli N" first="Nassim" last="Morsli">Nassim Morsli</name>
<affiliation><nlm:affiliation>Boehringer Ingelheim France S.A.S., Paris/FRANCE.</nlm:affiliation>
<wicri:noCountry code="subField">Paris/FRANCE</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Velema, Derek" sort="Velema, Derek" uniqKey="Velema D" first="Derek" last="Velema">Derek Velema</name>
<affiliation><nlm:affiliation>Boehringer Ingelheim (Canada) Ltd./Ltée, Burlington/ON/CANADA.</nlm:affiliation>
<wicri:noCountry code="subField">Burlington/ON/CANADA</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Popat, Sanjay" sort="Popat, Sanjay" uniqKey="Popat S" first="Sanjay" last="Popat">Sanjay Popat</name>
<affiliation><nlm:affiliation>Royal Marsden Hospital NHS Foundation Trust, London and Surrey/UNITED KINGDOM.</nlm:affiliation>
<wicri:noCountry code="subField">London and Surrey/UNITED KINGDOM</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</title>
<idno type="eISSN">1556-1380</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C17 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 003C17 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:27676538 |texte= P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:27676538" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |